Plasma tau protein and Aβ42 level as markers of cognitive impairment in patients with Parkinson’s disease

Chojdak-Łukasiewicz, Justyna; Małodobra-Mazur, Małgorzata; Zimny, Anna; Noga, Leszek; Paradowski, Bogusław

doi:10.17219/acem/112058

Cited by 20 publications

(15 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent cross‐sectional study concluded no correlations between the levels of plasma Aβ42 and t‐tau and cognitive deficits in PD subjects, with variable plasma values detected 24 . In our study, a higher level of plasma t‐tau was associated with worse attention and executive function, although no significant correlations were found between plasma Aβ42 and any of the cognition domains.…”

Section: Discussioncontrasting

confidence: 72%

See 1 more Smart Citation

Plasma total tau predicts executive dysfunction in Parkinson's disease

Lin

Shaw

Cheng

et al. 2021

Acta Neuro Scandinavica

View full text Add to dashboard Cite

Parkinson's disease (PD) is a progressive neurodegenerative disease.In addition to motor dysfunction, cognitive impairment is an important non-motor aspect that affects the quality of life in patients with PD, and predominantly involves the cognition domains of attention, executive function, and visuospatial skills. 1,2 α-synuclein (α-syn), which plays a major role in the pathogenesis of idiopathic PD, 3 can be detected in central and peripheral tissues. 4 Nowadays, the variable results of the cerebrospinal fluid (CSF) α-syn values among previous studies have made it difficult to be regarded as a diagnostic biomarker for PD. 5,6 More longitudinal studies are needed to investigate the values in different stages of PD. However, the invasive procedure of obtaining CSF hinders from achieving a larger sample size. Plasma α-syn, which is more accessible than CSF α-syn, has gained focus in recent years; nevertheless, inconsistent findings in patients with PD have been reported. 5,6 Besides, limited studies investigated the relationships between the levels of plasma α-syn and motor dysfunction [7][8][9] or cognitive deficits in PD individuals. 8,[10][11][12]

show abstract

Section: Discussioncontrasting

confidence: 72%

“…Limited studies investigated the relationships between the plasma values of Aβ and tau proteins and cognitive deficits in patients with PD. 10,24,25 Furthermore, studies to discuss the correlations between the plasma biomarkers and specific cognition domains in PD subjects are still lacking.…”

mentioning

confidence: 99%

Plasma total tau predicts executive dysfunction in Parkinson's disease

Lin

Shaw

Cheng

et al. 2021

Acta Neuro Scandinavica

View full text Add to dashboard Cite

show abstract

“…On the one hand, overproduction or impaired elimination of Aβ can also occur in other diseases. Increased amyloid peptide concentrations were found in patients diagnosed with liver tumors [23], kidney [24] and liver [25] failure, Parkinson's disease [26], obesity and insulin resistance [27], or Down Syndrome [28]. On the other hand, a decrease in Aβ42 levels in the serum has been observed in depression [29].…”

Section: Amyloid Beta and Its Role In Dementia Processmentioning

confidence: 99%

Diagnostic Utility of Selected Serum Dementia Biomarkers: Amyloid β-40, Amyloid β-42, Tau Protein, and YKL-40: A Review

Wilczyńska

Waszkiewicz

2020

JCM

View full text Add to dashboard Cite

Introduction: Dementia is a group of disorders that causes dysfunctions in human cognitive and operating functions. Currently, it is not possible to conduct a fast, low-invasive dementia diagnostic process with the use of peripheral blood biomarkers, however, there is a great deal of research in progress covering this subject. Research on dementia biomarkers in serum validates anticipated health and economic benefits from early screening tests. Biomarkers are also essential for improving the process of developing new drugs. Methods: The result analysis, of current studies on selected biomarker concentrations (Aβ40, Aβ42, t-tau, and YKL-40) and their combination in the serum of patients with dementia and mild cognitive disorders, involved a search for papers available in Medline, PubMed, and Web of Science databases published from 2000 to 2020. Results: The results of conducted cross-sectional studies comparing Aβ40, Aβ42, and Aβ42/Aβ40 among people with cognitive disorders and a control group are incoherent. Most of the analyzed papers showed an increase in t-tau concentration in diagnosed Alzheimer’s disease (AD) patients’ serum, whereas results of mild cognitive impairment (MCI) groups did not differ from the control groups. In several papers on the concentration of YKL-40 and t-tau/Aβ42 ratio, the results were promising. To date, several studies have only covered the field of biomarker concentrations in dementia disorders other than AD. Conclusions: Insufficient amyloid marker test repeatability may result either from imperfection of the used laboratorial techniques or inadequate selection of control groups with their comorbidities. On the basis of current knowledge, t-tau, t-tau/Aβ42, and YKL-40 seem to be promising candidates as biomarkers of cognitive disorders in serum. YKL-40 seems to be a more useful biomarker in early MCI diagnostics, whereas t-tau can be used as a marker of progress of prodromal states in mild AD. Due to the insignificant number of studies conducted to date among patients with dementia disorders other than AD, it is not possible to make a sound assessment of their usefulness in dementia differential diagnostics.

show abstract

“…Additionally, a lot of the biological processes and genes we found in our PD network has been implicated in the PD brain previously [11]. Tau and Aβ are hallmarks of both AD and PD in the brain and have potential as blood biomarkers in both diseases [50,51], suggesting that changes in the brain are reflected in blood.…”

Section: Discussionmentioning

confidence: 89%

Genetic networks in Parkinson’s and Alzheimer’s disease

Kelly

Moyeed

Carroll

et al. 2020

Aging

View full text Add to dashboard Cite

Parkinson's disease (PD) and Alzheimer's disease (AD) are the most common neurodegenerative diseases and there is increasing evidence that they share common physiological and pathological links. Here we have conducted the largest network analysis of PD and AD based on their gene expressions in blood to date. We identified modules that were not preserved between disease and healthy control (HC) networks, and important hub genes and transcription factors (TFs) in these modules. We highlighted that the PD module not preserved in HCs was associated with insulin resistance, and HDAC6 was identified as a hub gene in this module which may have the role of influencing tau phosphorylation and autophagic flux in neurodegenerative disease. The AD module associated with regulation of lipolysis in adipocytes and neuroactive ligand-receptor interaction was not preserved in healthy and mild cognitive impairment networks and the key hubs TRPC5 and BRAP identified as potential targets for therapeutic treatments of AD. Our study demonstrated that PD and AD share common disrupted genetics and identified novel pathways, hub genes and TFs that may be new areas for mechanistic study and important targets in both diseases.

show abstract

Plasma tau protein and Aβ42 level as markers of cognitive impairment in patients with Parkinson’s disease

Cited by 20 publications

References 32 publications

Plasma total tau predicts executive dysfunction in Parkinson's disease

Plasma total tau predicts executive dysfunction in Parkinson's disease

Diagnostic Utility of Selected Serum Dementia Biomarkers: Amyloid β-40, Amyloid β-42, Tau Protein, and YKL-40: A Review

Genetic networks in Parkinson’s and Alzheimer’s disease

Contact Info

Product

Resources

About